2044 POSTER Phase II trial with letrozole (2.5 mg) to maximal response as neoadjuvant endocrine therapy in postmenopausal patients with ER/PgR[+] operable breast cancer

✍ Scribed by A. Llombart Cussac; A. Galán; C. Fuster; E. Buch; V. Carañana; A. Rodríguez Lescure; C. Vázquez; A. Guerrero; A. Ruiz; V. Guillem Porta

• Book ID: 118625648
• Publisher: Elsevier Science
• Year: 2007
• Tongue: English
• Weight: 56 KB
• Volume: 5
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(07)70806-6